Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients
D. Sprecher,J. Abrams,J. Allen,William E. Keane,S. Chrysant,H. Ginsberg,J. Fischer,B. Johnson,P. Théroux,L. Jokubaitis
DOI: https://doi.org/10.7326/0003-4819-120-7-199404010-00002
IF: 39.2
1994-04-01
Annals of Internal Medicine
Abstract:Table. SI Units and Drugs Many reports have shown the efficacy of the combination of bile-absorbing resin and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin class) therapies [1-4]. Primarily, this resin-statin treatment regimen has been targeted to patients with low-density lipoprotein (LDL) cholesterol levels greater than 6.47 mmol/L (>250 mg/dL), a population presumably enriched with familial hypercholesterolemic patients. Consequently, dosages have been large, with both the statin and resin agents administered at the upper ends of their respective dosing ranges. However, this group of markedly hypercholesterolemic patients does not represent the typical person identified through the adult National Cholesterol Education Program guidelines. For the considerably larger pool of persons with LDL cholesterol between 4.14 mmol/L and 6.21 mmol/L (160 mg/dL and 240 mg/dL), a safe, convenient, well-tolerated, and effective dosing method is essential. Low-dose combination therapy is thought to be beneficial because long-term compliance is enhanced and safety maximized while efficacy is preserved. It has been suggested that side effects with statin agents are dose-dependent, thereby implying a benefit with routine use of lower dosing. In contrast, side effects attributed to resin are equivalent at varying doses within the usual dosing range [5, 6]. Thus, the benefit of lower resin dose would be confined to enhanced palatability and tolerability. The overall cholesterol lowering with such a low-dose combination, however, still remains unknown. Fluvastatin sodium (Lescol, Sandoz; East Hanover, New Jersey), a new water-soluble cholesterol-lowering agent that acts through the inhibition of HMG-CoA reductase, is the first entirely synthetic HMG-CoA reductase inhibitor and differs structurally from the fungal derivatives of compactin [7]. Fluvastatin has a distinctive biopharmaceutical profile; it has a high rate of absorption that is not influenced by food intake, possesses no circulating active metabolites, is 98% protein-bound, does not cross the blood-brain barrier, has a systemic half-life of 30 minutes, and is 95% excreted by the liver [8]. We evaluated the LDL cholesterol-lowering efficacy of various combinations of low-dose resin and statin treatments, using cholestyramine (Questran Light; Bristol) and fluvastatin. The study population included mostly patients with hypercholesterolemia who would, according to the new National Cholesterol Education Program guidelines for adults (LDL cholesterol > 4.91 mmol/L [>190 mg/dL] or LDL cholesterol > 4.14 mmol/L [>160 mg/dL] with two risk factors), be advised to receive medication. Methods The study protocol was designed by mutual consent of the investigators and Sandoz Research Institute, with all data collected by the investigators subject to review and analysis by Sandoz Research Institute. The interpretation of the data in this article is based on the mutual consent of all submitting authors. All patients were consecutively randomized based on a diagnosis of hypercholesterolemia confirmed during drug washout with an LDL cholesterol level of at least 4.14 mmol/L (160 mg/dL), despite dietary intervention, and a plasma triglyceride level of no more than 3.39 mmol/L (300 mg/dL). Persons were excluded if they had a history of homozygous familial hypercholesterolemia, secondary hyperlipidemia, liver disease, renal disease, diabetes, myocardial infarction or angioplasty within 6 months of study entry, or uncontrolled hypertension. The patients' mean age was 54.1 years; 54% were male; 95% were white and 3% were black. The treatment groups did not differ in baseline demographic characteristics. The study was approved by the institutional review boards for human research of all participating institutions. Informed consent was obtained from all patients. Treatment Plan This study consisted of a 6-week, single-blind, placebo washout period followed by a 24-week, double-blind treatment period divided into three phases (Figure 1). Patients were withdrawn from hypolipidemic therapy for at least 4 weeks (1 year for probucol) before entry into the washout period. In addition, patients were instructed by a registered dietitian to follow a cholesterol-lowering diet (American Heart Association or National Cholesterol Education Program step 1) for at least 8 weeks before entry into the washout period and throughout the study, and a Food Record Rating score of 15 or less was required for study entry [9]. Patients with aspartate aminotransferase or alanine aminotransferase values greater than 1.5 times the upper limit of laboratory normal during the washout period were excluded from the study. Figure 1. Study design and numbers of patients initially assigned to each treatment group. At the end of the placebo washout period, patients who satisfied all entry criteria entered the 24-week, double-blind treatment period, which consisted of three 8-week phases. For the first 8 weeks (phase 1), patients were assigned randomly into six groups receiving blinded study medication: two groups receiving placebo; two receiving 10 mg of fluvastatin; and two receiving 20 mg of fluvastatin. In phases 2 and 3 of the study, one placebo group, one 10-mg fluvastatin group, and one 20-mg fluvastatin group received open-label cholestyramine in addition to the blinded study drug, whereas the other three groups remained on fluvastatin or placebo monotherapy for the rest of the trial. In phase 2, the dose of cholestyramine added to the regimen of patients in the three combination groups was 4 g twice daily. In phase 3, the dose of cholestyramine was increased to 8 g twice a day for these patients. Blinded medication was taken once daily at bedtime, approximately 4 hours after the evening meal. Patients receiving open-label cholestyramine took their medication just before breakfast and dinner. Compliance with all treatment regimens was assessed by pill or packet count. Study Evaluations Patients were assessed every 2 weeks during the placebo washout period and every 4 weeks during the 24-week treatment period. Dietary compliance was determined by Food Record Rating scores derived from dietary records collected throughout the study [9]. Twelve-hour fasting blood samples were obtained at each visit for lipid determinations, which were done by a central laboratory (Medical Research Laboratories; Cincinnati, Ohio). Low-density lipoprotein cholesterol was calculated according to the Friedewald formula [10]. Total cholesterol, high-density lipoprotein cholesterol, and plasma triglycerides were measured on a 737 Hitachi analyzer (Boehringer Mannheim Diagnostics; Indianapolis, Indiana) with microenzymatic procedures [11] fully standardized, and part 3 was monitored through the National Heart, Lung, and Blood Institute and Centers for Disease Control and Prevention Lipid Standardization Program [12, 13]. Safety was evaluated at baseline and at intervals throughout the study. These evaluations included measurements of blood pressure and pulse; physical, ophthalmologic, and electrocardiographic examinations; and routine laboratory tests. Investigators were asked to assess, in a blinded fashion, each adverse event and laboratory abnormality for a potential relation to blinded study drug administration, based on their clinical experience and judgment. Statistical Analysis All statistical comparisons were made using two-tailed tests at the P < 0.05 level. Data were pooled across all clinical centers for analysis. The Statistical Analysis System (SAS Institute, Inc.; Cary, North Carolina) software was used for all analyses. All confidence intervals are 95% and represent the difference in mean percent change from baseline between two treatment groups of interest. For each patient, the baseline lipid value was defined as the average of the week 2 and week 0 lipid measurements during the washout phase. In evaluating efficacy by treatment phase, lipid results were calculated as the averages of the values for weeks 4 and 8, weeks 12 and 16, and weeks 20 and 24. For end-point analyses, the end point was defined as the last active treatment phase visit for which lipid data were available. One-way analysis of variance models were used to compare the mean percentage change in total cholesterol, LDL cholesterol, high-density lipoprotein cholesterol, and triglycerides between the treatment groups. In each model, we did tests of significance of the percentage change from baseline within each group and of differences in mean percentage change between treatment groups. In determining safety, a newly occurring abnormality was defined as an abnormality reported during the active treatment period but not reported during the placebo washout period, and a worsening abnormality was an abnormality that worsened from the placebo washout period to the active treatment period. The number of patients with newly occurring or worsening abnormalities in each treatment group was determined, and the proportions were compared using the Fisher exact test. Results Of 460 patients from nine study centers screened, 224 met study criteria and were randomized into the double-blind treatment period of this study; 203 completed all phases of treatment. Fifteen (10%) of 150 fluvastatin-treated patients and 6 (8%) of 74 placebo- or cholestyramine-treated or both (that is, non-fluvastatin-treated) patients were dropped during the double-blind treatment period. Five fluvastatin-treated patients (1 receiving concomitant cholestyramine) and 1 placebo-treated patient (receiving concomitant cholestyramine) dropped out because of adverse events. These events, each of which occurred in one patient, were angina, myalgia, stomatitis and glossitis, heartburn and indigestion, elevated transaminase levels, and alopecia. Of these, only the instance of stomatitis and glossitis was judged by the investigator to be definitely related to the drug. One patient recei